Abstract
In Europe, modified live vaccines (MLV) are commonly used to control porcine reproductive and respiratory syndrome virus (PRRSV) infection. However, they have been associated with safety issues such as reversion to virulence induced by mutation and/or recombination. On a French pig farm, we identified a field recombinant strain derived from two PRRSV-1 MLV (MLV1). As a result, we aimed to evaluate its clinical, virological, and transmission parameters in comparison with both parental strains. Three groups with six pigs in each were inoculated with either one of the two MLV1s or with the recombinant strain; six contact pigs were then added into each inoculated group. The animals were monitored daily for 35 days post-inoculation (dpi) for clinical symptoms; blood samples and nasal swabs were collected twice a week. PRRS viral load in inoculated pigs of recombinant group was higher in serum, nasal swabs, and tonsils in comparison with both vaccine groups. The first viremic contact pig was detected as soon as 2 dpi in the recombinant group compared to 10 and 17 dpi for vaccine groups. Estimation of transmission parameters revealed fastest transmission and longest duration of infectiousness for recombinant group. Our in vivo study showed that the field recombinant strain derived from two MLV1s demonstrated high viremia, shedding and transmission capacities.
Highlights
Porcine reproductive and respiratory syndrome (PRRS) is endemic in most pig-producing countries worldwide and is reported to be among the diseases with the highest economic impact in the modern pig industry [1,2]
Recombination is an important genetic mechanism contributing to the evolution of PRRS virus (PRRSV) and 3 to emergence of novel strains, potentially exhibiting leading increased virulence [14]
6.115.10 transmission were measured and compared between a recombinant PRRSV strain isolated from the field and both parental modified live PRRSV-1 vaccines (MLV1s) strains
Summary
Porcine reproductive and respiratory syndrome (PRRS) is endemic in most pig-producing countries worldwide and is reported to be among the diseases with the highest economic impact in the modern pig industry [1,2]. The disease is mainly characterized by reproductive failure in pregnant. PRRSV strains are divided into PRRSV-1 (mainly predominant in Europe) and PRRSV-2. Since the emergence of PRRS, several modified live PRRSV-1 vaccines (MLV1s), i.e., live attenuated viral strains, have been licensed. They are currently frequently used as a tool to reduce the clinical impact of PRRSV infection and to control the within-herd dynamics of infection [9]. The current MLVs have been associated with certain safety concerns such as reversion to virulence [10]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
